# This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

> **NCT03343704** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 19 (actual)

## Conditions studied

- Hemorrhage

## Interventions

- **DRUG:** Idarucizumab

## Key facts

- **NCT ID:** NCT03343704
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-26
- **Primary completion:** 2020-07-02
- **Final completion:** 2020-07-02
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03343704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03343704, "This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03343704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*